Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

SEATTLE--(BUSINESS WIRE)--Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of a fully integrated immune repertoire and ...

In The Descent, an outdoor adventure goes terribly wrong for six friends who enter caves looking for fun but find murderous creatures within the depths. Jen Karner has spent the last 10 years covering ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

When adventurers talk about Mount Everest, most often it's about climbing the world's highest peak. In October, Jim Morrison became the first person to ski down Everest’s most dangerous route. The ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

LOS ANGELES, Oct. 22 (UPI) --Revisiting The Descent, returning to U.K. theaters Friday for the 20th anniversary of its original U.K. release, is a celebration of the survival horror film's visceral ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...